文献速递妇科

卡博替尼对比每周紫杉醇治疗持续性或复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌的随机II期研究:NRG肿瘤学/妇科肿瘤学组研究

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
PubMed 文献 · Gynecol Oncol · 2018-12-23

这项开放标签1:1随机II期研究纳入111例持续性或复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,比较卡博替尼60 mg每日口服与每周紫杉醇80 mg/m²(每4周给药3周)。两组中位无进展生存期相似(5.3个月 vs 5.5个月),但卡博替尼组总生存期、无事件生存期和客观缓解率均更差,胃肠道毒性更重。作者结论认为该剂量和方案的卡博替尼不能推荐用于复发性卵巢癌治疗。

要点

  • 卡博替尼组与每周紫杉醇组中位无进展生存期相似:5.3个月 vs 5.5个月(HR 1.11,90%CI 0.77-1.61,p=0.64)。
  • 卡博替尼组中位总生存期19.4个月,每周紫杉醇组未达到(HR 2.27,90%CI 1.17-4.41,p=0.04)。
  • 卡博替尼组客观缓解率7%,低于每周紫杉醇组的24.1%;恶心、腹泻、腹痛等胃肠道毒性在卡博替尼组更重。

核心结论

  • 卡博替尼与每周紫杉醇的中位无进展生存期相似,但卡博替尼组总生存期、无事件生存期和客观缓解率均更差。
  • 作者结论认为,该剂量和方案的卡博替尼不能推荐作为复发性卵巢癌的治疗。

研究设计与样本

  • 开放标签、1:1随机II期研究(NCT01716715),共纳入111例患者。
  • 入组条件为持续性或复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌,且既往接受至少1个但不超过3个化疗方案。
  • 干预为卡博替尼60 mg每日口服 vs 每周紫杉醇80 mg/m²,每4周给药3周。

主要发现

  • 中位无进展生存期:卡博替尼组5.3个月 vs 每周紫杉醇组5.5个月(HR 1.11,90%CI 0.77-1.61,p=0.64)。
  • 中位总生存期:卡博替尼组19.4个月 vs 每周紫杉醇组未达到(HR 2.27,90%CI 1.17-4.41,p=0.04)。
  • 中位无事件生存期:卡博替尼组3.5个月 vs 每周紫杉醇组5.0个月(HR 1.81,90%CI 1.24-2.63,p=0.01)。
  • 客观缓解率:卡博替尼组7% vs 每周紫杉醇组24.1%。
  • 胃肠道毒性(恶心、腹泻、腹痛)在卡博替尼组更重。

临床怎么用

  • 原文结论认为,该剂量和方案的卡博替尼不能推荐作为复发性卵巢癌的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer. METHODS: This was an open label, 1:1 randomized study of cabozantinib 60 mg orally (PO) daily versus weekly paclitaxel 80 mg/m2 given 3 out of 4 weeks (NCT01716715); 111 patients were enrolled. Eligibility included persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and at least one but no >3 prior chemotherapy regimens. RESULTS: Median PFS was similar for both treatment groups and was 5.3 months for cabozantinib and 5.5 months for weekly paclitaxel (HR 1.11 (90% CI 0.77-1.61, p = 0.64)). Secondary analyses of overall survival (OS) and event free survival (EFS) showed that cabozantinib did not perform as well as weekly paclitaxel. Median OS for cabozantinib was 19.4 months and was not reached for weekly paclitaxel (HR 2.27 (90% CI 1.17-4.41, p = 0.04). EFS was also worse in the cabozantinib arm, 3.5 months, compared to weekly paclitaxel at 5.0 months (HR 1.81 (90% CI 1.24-2.63, p = 0.01). Overall response rate (ORR) was less for cabozantinib compared to weekly paclitaxel (7% versus 24.1%). Gastrointestinal toxicities, specifically nausea, diarrhea, and abdominal pain were worse in the cabozantinib arm. CONCLUSIONS: Median PFS was similar for cabozantinib and weekly paclitaxel. However, OS, EFS, and ORR were worse for cabozantinib compared to weekly paclitaxel. Cabozantinib given at this dose and schedule cannot be recommended as a treatment for recurrent ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matulonis UA, Sill MW, Makker V, et al. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018. PMID: 30587441. doi:10.1016/j.ygyno.2018.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。